Clinical Trial Update: MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning using treosulfan and fludarabine, followed by po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Treosulfan (treosulfan)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: AML, MDS | Phase 2 | Status: RECRUITING